Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Recipient : Celmatix
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Ache, for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
August 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Recipient : Celmatix
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.
Brand Name : ACH000029
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : Nemera
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually aft...
Brand Name : Clilon
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 06, 2021
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Nemera
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?